Lataa...
Prospects for combining immune checkpoint blockade with PARP inhibition
The immunogenicity of a cancer cell is derived from accumulated somatic mutations. However, on the contrary to increased immunogenicity, anti-cancer immune response tends to be feeble. This impaired anti-cancer immunity could be attributed to multiple factors including loss of immunodominant epitope...
Tallennettuna:
| Julkaisussa: | J Hematol Oncol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6744711/ https://ncbi.nlm.nih.gov/pubmed/31521196 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0784-8 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|